LISATA THERAPEUTICS INC (LSTA) Stock Price, Quote, News and Overview
NASDAQ:LSTA - Nasdaq - US1280583022 - Common Stock - Currency: USD
LSTA Quote, Performance and Key Statistics
NASDAQ:LSTA (6/16/2025, 2:29:05 PM)
2.49
-0.01 (-0.4%)
The current stock price of LSTA is 2.49 USD. In the past month the price increased by 3.96%. In the past year, price decreased by -30.69%.
LSTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.59 | 337.28B | ||
| AMGN | AMGEN INC | 14.21 | 158.59B | ||
| GILD | GILEAD SCIENCES INC | 14.23 | 137.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.88 | 56.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.30B | ||
| ARGX | ARGENX SE - ADR | 97.05 | 34.07B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.77 | 28.63B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.50B | ||
| NTRA | NATERA INC | N/A | 22.95B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 18.31B |
Related stock screener links
About LSTA
Company Profile
Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Company Info
LISATA THERAPEUTICS INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY US
Employees: 26
Phone: 19082292590
LISATA THERAPEUTICS INC / LSTA FAQ
What is the stock price of LISATA THERAPEUTICS INC today?
The current stock price of LSTA is 2.49 USD. The price decreased by -0.4% in the last trading session.
What is the ticker symbol for LISATA THERAPEUTICS INC stock?
The exchange symbol of LISATA THERAPEUTICS INC is LSTA and it is listed on the Nasdaq exchange.
On which exchange is LSTA stock listed?
LSTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LISATA THERAPEUTICS INC stock?
9 analysts have analysed LSTA and the average price target is 17 USD. This implies a price increase of 582.73% is expected in the next year compared to the current price of 2.49. Check the LISATA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LISATA THERAPEUTICS INC worth?
LISATA THERAPEUTICS INC (LSTA) has a market capitalization of 21.41M USD. This makes LSTA a Nano Cap stock.
How many employees does LISATA THERAPEUTICS INC have?
LISATA THERAPEUTICS INC (LSTA) currently has 26 employees.
What are the support and resistance levels for LISATA THERAPEUTICS INC (LSTA) stock?
LISATA THERAPEUTICS INC (LSTA) has a support level at 2.48 and a resistance level at 2.61. Check the full technical report for a detailed analysis of LSTA support and resistance levels.
Should I buy LISATA THERAPEUTICS INC (LSTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LSTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LSTA, evaluating the profitability, health, valuation and growth aspects
- LISATA THERAPEUTICS INC (LSTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LISATA THERAPEUTICS INC (LSTA) Sales and EPS estimates to see what analysts future expectations are.
- LISATA THERAPEUTICS INC (LSTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LISATA THERAPEUTICS INC (LSTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- LISATA THERAPEUTICS INC (LSTA) Stock Chart to make your own analysis
- LISATA THERAPEUTICS INC (LSTA) Latest news and press-releases to stay up to date.
Does LISATA THERAPEUTICS INC (LSTA) stock pay dividends?
LSTA does not pay a dividend.
When does LISATA THERAPEUTICS INC (LSTA) report earnings?
LISATA THERAPEUTICS INC (LSTA) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of LISATA THERAPEUTICS INC (LSTA)?
LISATA THERAPEUTICS INC (LSTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.3).
What is the Short Interest ratio of LISATA THERAPEUTICS INC (LSTA) stock?
The outstanding short interest for LISATA THERAPEUTICS INC (LSTA) is 0.34% of its float. Check the ownership tab for more information on the LSTA short interest.
LSTA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LSTA. When comparing the yearly performance of all stocks, LSTA is a bad performer in the overall market: 80.34% of all stocks are doing better.
LSTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSTA. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LSTA Financial Highlights
Over the last trailing twelve months LSTA reported a non-GAAP Earnings per Share(EPS) of -2.3. The EPS increased by 6.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.1% | ||
| ROE | -67.58% | ||
| Debt/Equity | 0 |
LSTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to LSTA. The Buy consensus is the average rating of analysts ratings from 9 analysts.